FIELD: pharmacology.
SUBSTANCE: invention relates to a new succinate salt of dimethylamide 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid represented by the formula (II)
in a hydrated and non-hydrated form. The compound can be used to treat a disease impaired by cyclin-dependent kinases activity inhibition, in particular, CDK1, CDK2, CDK3, CDK4 CDK5, CDK6 and CDK9 kinases. Such a disease can be represented by breast cancer, genitourinary cancer, lung cancer, pancreatic cancer, etc. The succinate salt corresponds to the structural formula given below.
EFFECT: increased efficiency of treatment.
5 cl, 6 dwg, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION INCLUDING CYCLIN-DEPENDENT KINASE 4 INHIBITOR OR CYCLIN-DEPENDENT KINASE 6 INHIBITOR (CDK4/6) AND mTOR INHIBITOR FOR TREATING CANCER | 2011 |
|
RU2589696C2 |
| ISETHIONATE SALT OF CDK4 SELECTIVE INHIBITOR | 2004 |
|
RU2317296C2 |
| PYRIDINE DERIVATIVES CONDENSED WITH HETEROCYCLE | 1996 |
|
RU2136683C1 |
| QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | 2015 |
|
RU2721723C2 |
| PYRROLOPYRIMIDINE COMPOUND | 2015 |
|
RU2701206C2 |
| CERTAIN PROTEIN KINASE INHIBITORS | 2015 |
|
RU2671494C2 |
| PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | 2014 |
|
RU2677653C2 |
| SOLID FORMS OF SELECTIVE CDK4/6 INHIBITOR | 2014 |
|
RU2619944C2 |
| RMT5 INHIBITORS | 2019 |
|
RU2814198C2 |
| (1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-d]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE HYDROCHLORIDE | 2010 |
|
RU2562245C2 |
